U.K. Government To Increase NTD Spending Fivefold Between 2011 And 2015

“The U.K. government has announced a fivefold increase in spending on combating neglected tropical diseases [NTDs] as part of an international effort to help rid the world of a group of infectious diseases that currently affect one billion people and kill more than half a million every year,” BMJ reports (Moszynski, 1/23). “International Development Minister Stephen O’Brien said funding for [NTDs] is to increase from £50 million to £245 million [approximately $381.5 million] between 2011 and 2015 as part of a global push to eradicate diseases including river blindness and elephantiasis,” the Press Association writes.

“The extra money will help supply more than four treatments every second for people in the developing world for the next four years, protecting more than 140 million people,” according to the news agency, which adds the programs will focus on lymphatic filariasis (elephantiasis), onchocerciasis (river blindness), schistosomiasis (bilharzia) and dracunculiasis (Guinea worm) (1/21). The announcement “comes ahead of a conference in London on January 30 when the Bill & Melinda Gates Foundation, governments, [non-governmental organizations], multilateral organizations and the private sector will unite to help consign the diseases to history,” according to a U.K. Department for International Development (DFID) press release (.pdf) (1/21).

The KFF Daily Global Health Policy Report summarized news and information on global health policy from hundreds of sources, from May 2009 through December 2020. All summaries are archived and available via search.

KFF Headquarters: 185 Berry St., Suite 2000, San Francisco, CA 94107 | Phone 650-854-9400
Washington Offices and Barbara Jordan Conference Center: 1330 G Street, NW, Washington, DC 20005 | Phone 202-347-5270

www.kff.org | Email Alerts: kff.org/email | facebook.com/KFF | twitter.com/kff

The independent source for health policy research, polling, and news, KFF is a nonprofit organization based in San Francisco, California.